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Background: Recurrent C. difficile infection (CDI) is a growing medical concern with poor 
response to standard antimicrobial therapy. We aimed to investigate the outcomes of fecal 
microbiota transplant (FMT) for relapsing CDI using a frozen suspension from unrelated donors, 
comparing colonoscopic and nasogastric-tube (NGT) administration.  
Methods: Healthy volunteer donors were screened and a frozen fecal suspension was 
generated. Patients with relapsing/refractory CDI were randomized to receive an infusion of 
donor stools by colonoscopy or NGT. The primary endpoint was clinical resolution of diarrhea 
without relapse after 8 weeks. Secondary endpoints were self-reported health score using 
standardized questionnaires.  
Results: A total of 20 patients were enrolled, 10 in each treatment arm. Patients had a median 
(range) of 4 (2-16) relapses prior to study enrollment, with 5 (3-15) antibiotic treatment 
failures. Resolution of diarrhea was achieved in 14 (70%) after a single FMT (8 of 10 in the 
colonoscopy group and 6 of 10 in the NGT group). Five patients were retreated with 4 obtaining 
cure, resulting in an overall cure rate of 90%. Daily number of bowel movements changed from 
a median (IQR) of 7 (5-10) the day prior to FMT to 2 (1-2) after the infusion. Self-ranked health 
scores improved significantly from a median (IQR) of 4 (2-6) pre-transplant to 8 (5-9) post-
transplant. No serious or unexpected adverse events occurred.  
Conclusion: In our initial feasibility study FMT using a frozen inoculum from unrelated donors is 






Recurrent and refractory Clostridium difficile infection (CDI) is a growing medical concern with a 
recent dramatic increase in the number of patients globally [1–4]. In the United States the 
incidence of CDI has tripled over the last 15 years [3]. Response to standard antimicrobial 
therapy with oral vancomycin or metronidazole is suboptimal, with CDI recurring in up to 30% 
of individuals treated for a first episode. After two or more episodes of CDI the estimated risk 
for subsequent recurrence exceeds 60% with antimicrobial therapy [3,5–8]. Often patients with 
recurrent CDI are treated with prolonged administration of oral vancomycin with tapering of 
the medication over many months, but this approach is poorly studied. The emergence of a 
virulent strain of the organism (NAP1/BI/027) has been associated with even higher rates of 
treatment failure [9,10]. The consequences of recurrence can be devastating, resulting in life-
threatening illness, frequent hospitalizations and possible surgical interventions. In addition to 
individual morbidity and mortality, CDI taxes the medical system by requiring patient cohorting, 
leading to bed closures, delay of discharge, and additional contact precautions.  
Although the illness is toxin-mediated, overgrowth of the organism in the setting of dysbiosis is 
thought to be a key inciting event. Failure to reconstitute normal flora was shown to be a factor 
in severe, recurrent, and prolonged illness [13].  Fecal microbiota transplantation (FMT) - 
reconstitution of normal flora by a stool transplant from a healthy  individual - has been a 
successful therapeutic approach to recurrent/refractory CDI in animal studies [14], numerous 
case series [15–20] and, more recently, a single randomized clinical trial [21]. Even though an 
overall CDI resolution rate of about 90% has repeatedly been reported in published reviews and 
meta-analyses [22–25], practical and aesthetic barriers have hindered the widespread use of 
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FMT to date. Recruitment and screening of donors is a lengthy process associated with 
significant costs, thus preventing the use of FMT in acute situations. Establishing a repository of 
prescreened frozen donor stools could make this treatment available for a wider population. 
Furthermore, many questions remain regarding the optimal protocol donor screening, sample 
processing, route of administration and amount of fecal material instilled.  
In the current study we aimed to investigate the clinical outcomes of FMT for refractory or 
relapsing CDI using a frozen suspension from unrelated donors by both upper and lower 
gastrointestinal routes. 
Methods: 
This was an open-label, randomized, controlled trial evaluating the efficacy of FMT in treating 
relapsing or recurrent CDI in a pilot cohort of 20 patients, comparing colonoscopic and 
nasogastric-tube (NGT) administration. The study was approved by the Partners Human 
Research Committee as well as by the United States Food and Drug Administration (IND # 
15199) and registered at Clinical Trials.gov (NCT01704937). Candidates were recruited by 
referrals from colleagues at Partners’ Healthcare of which MGH is a founding member. All adult 
participants provided written informed consent after a clinical meeting with a physician 
investigator providing information about potential risks and benefits of the procedure. Children 
aged 7 and above provided assent, in addition to parental informed consent. Participants were 
allocated to treatment arms by computer-generated randomization in blocks of four.  
Study Population and Settings: The study was conducted at Massachusetts General Hospital. 
Included were subjects ages 7-90 with refractory or recurrent CDI, as defined in consensus 
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guidelines [26] by a relapse of CDI after having at least three episodes of mild-to-moderate CDI 
and failure of a 6-8 week taper with vancomycin with or without an alternative antibiotic, OR, 
at least two episodes of severe CDI resulting in hospitalization and associated with significant 
morbidity. Active CDI was defined as diarrhea (>3 loose stools per day) with a positive stool test 
for C.difficile toxin. Our hospital laboratory performs an initial toxin/glutamate dehydrogenase 
(GDH)  ELISA, followed by PCR if only the GDH test is positive or indeterminate and does not 
routinely test for the NAP-1/B1/207 strain. Exclusion criteria included presence of anatomic 
contraindication to NGT or colonoscopy, delayed gastric emptying syndrome, recurrent 
aspirations, pregnancy, significantly compromised immunity (immunosuppressive medications, 
recent chemotherapy, decompensated liver cirrhosis, advanced HIV/AIDS [CD4 count<250], 
neutropenia with ANC <1000/ul,  recent bone marrow transplant, or other cause of severe 
immunodeficiency) and having a history of significant allergy to foods not excluded from the 
donor diet. Stable oral prednisone treatment up to 40 mg daily was allowed.   
Donor Screening: Donors were healthy, non-pregnant adults 18-50 years of age, on no 
medications, with a normal Body Mass Index (BMI 18.5-25).  Volunteers were excluded for any 
significant past medical history (with the exception of resolved traumatic injury) or any use of 
antibiotics in the preceding 6 months. Candidates were initially screened using the American 
Association of Blood Banks donor questionnaire for exposure to infectious agents [27], then 
underwent physical examination and general laboratory screening tests (within 30 days of 
donations), including complete blood count with differential, renal function and electrolytes, 
complete liver function tests, albumin and total protein,  lipid profile, high resolution C-reactive 
protein, fluorescent anti-nuclear antigen, and fecal occult blood testing.  All results had to be 
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within normal range for age and gender. Donor feces were screened for enteric bacterial 
pathogens including rotavirus, Listeria  monocytogenes, and Vibrio cholerae, Escherichia coli 
O157,  ova and parasites (including general microscopy, acid-fast staining and/or antigen 
testing for giardia and cryptosporidium, isospora and microsporidia), C. difficile  and 
Helicobacter pylori antigen. Blood was screened for antibodies to hepatitis A, B and C; HIV and 
Treponema pallidum within 2 weeks of donations. The volunteers were asked to refrain from 
eating common allergens within 5 days of stool donation (tree nuts, eggs, peanuts, shellfish) 
but otherwise not to alter their diets.  At the time of donation they had an interim health query 
for febrile, systemic and GI symptoms and were deferred for any change in health status. 
Finally, all donations were escrowed for an additional four weeks, to allow re-testing of donors 
for HIV and hepatitis B and C prior to clinical use of the inoculum. 
Preparation of frozen inocula: Donors were asked to take a dose of Milk of Magnesia the day 
before fecal collections in order to facilitate manipulation of the sample. A fecal suspension was 
generated in normal saline without preservatives, using a commercial blender. Materials were 
sequentially passed through four sieves to remove particulate material. The final slurry was 
concentrated 3-fold by centrifugation and then re-suspended in sterile saline with 10% glycerol 
added as a bacterial cryoprotectant. Inocula were then frozen at -80o C pending use. The work 
of Hamilton and Khoruts [28] was used as a guide for  fecal manipulation, with the exception 
that all processes were carried out under ambient air, not nitrogen.  Each sieved inoculum was 
calculated at the conclusion of the project to have been derived from approximately 41 grams 
of fecal material. Inocula used in this study were stored frozen for up to 156 days (range 29-
156). Frozen material was thawed in a 370c water bath, and then kept on ice until delivery.  
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Study procedures: (Supplementary Figure S1) Patients were required to discontinue all 
antibiotics at least 48 hours prior to the procedure. Subjects assigned to colonoscopic 
administration underwent a standard bowel preparation with four liters of Polyethylene glycol 
electrolyte solution, followed by endoscopic administration to the right colon of 90cc thawed 
inoculum. This amount of fecal material was further diluted to 250cc for adults and 160 cc for 
pediatric patients. Patients were asked to retain the material as long as possible post-procedure 
and were given a single oral dose of loperamide at the time of the procedure. Subjects assigned 
to NGT delivery of FMT were prescribed 2 mg/kg/day up to 20 mg of omeprazole orally for 48 
hours prior to the procedure. An age and size-appropriate NGT was inserted, proper positioning 
in the stomach was documented by radiography and 90cc inoculum was administered. In these 
patients the inoculum was not further diluted, in order to minimize risk of vomiting and 
aspiration. The NGT was removed promptly after administration and subjects were asked to 
drink a glass of water to facilitate dilution of stomach contents and transit into the small 
intestine.  
Patients in both study arms that showed no improvement in diarrheal symptoms were offered 
a second FMT by their preferred route of administration. In order to minimize potential 
infectious exposures, inoculum from the same donor was used for the repeat administration.  
Patients in both groups were followed with structured questionnaires administered on days 1, 
2, 3, 7, 14, 21 and at 2 and 6 months after the procedure (primarily by phone). Questionnaires 
recorded stool frequency and consistency, general well-being on a standardized health score, 
rating of gastrointestinal symptoms, medication use, weight changes, and elicited possible 
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adverse events by use of a modification of the Common Terminology Criteria for Adverse 
Events v3.0 [29] approved by the FDA and IRB.  
Outcomes: The primary endpoint was clinical resolution of diarrhea off antibiotics for C. 
difficile, without relapse within 8 weeks. For patients that required a second treatment dose, 
follow up was calculated starting at the time of the second administration. Resolution of 
diarrhea was defined as fewer than three bowel movements per 24hrs. Secondary endpoints 
included improvement in subjective well-being per standardized questionnaire and presence of 
adverse events. 
Data analysis: Continuous variables are presented as mean and standard deviation (SD), 
median and interquartile range (IQR). Categorical variables are presented as number and 
percentage of patients within each treatment group. Patient characteristics at baseline were 
compared between the two treatment groups in order to estimate the efficacy of  
randomization. The Mann-Whitney test was used for comparisons of continuous variables 
(patient characteristics and outcomes) between the two treatment groups and Fisher’s exact 
test for comparisons of categorical variables. Outcomes were analyzed according to the 
intention-to-treat principle, with imputation of data by the last outcome carried forward. A 
mixed-model ANOVA was used to estimate difference in outcomes between the two treatment 
groups over the study time. 
All statistical tests were two-sided; a p-value < 0.05 was considered statistically significant. Data 
were analyzed using SPSS statistical software version 21 (SPSS Inc., Chicago, IL, USA). 
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Analysis of fecal microbiota: A donor sample was collected at time of donation. Recipients 
provided stool samples before FMT, weekly for three weeks and then at 2 and 6 months. All 
fecal samples were stored at -80 C. DNA was extracted and the V4 region of the 16S gene was 
sequenced using an Illumina MiSeq (Illumina, San Diego, CA) as described previously [30].  The 
Shanon Diversity Index was computed for each sample and a custom python script was used to 
create summary plots illustrating the relationship between clinically relevant groupings and the 
diversity observed in the microbiome. We used the Shannon Diversity Index as our primary 
measure of diversity because it takes into account both abundance and evenness of species 
present in the community and has been shown to most robustly accommodate the variation in 
sampling depth [31]. See Supplementary Appendix 1 for detailed methods. 
Results: 
From December 2012 through May 2013, a total of 20 patients were randomly assigned to 
receive FMT via colonoscopy or NGT (Fig. 1). Baseline characteristics were comparable between 
groups (Table 1). 
Donors: Of 37 candidates that responded to our call for volunteers, 12 passed the initial 
screening and underwent a full donor work-up. Seven were excluded from donating based on 
abnormal screening labs: 4 with positive anti-nuclear antibodies, 1 with elevated bilirubin, 1 
with mild neutropenia and 1 with eosinophilia. The remaining 5 donors provided 3 stool 
samples each, that were used to generate 25 infusions used in 20 study patients. 
Primary Outcome: Of 20 patients in both study arms, 14 were cured after the first infusion of 
donor feces (70%); 8 in the colonoscopy group (80%) and 6 in the NGT group (60%; p=0.628). 
One patient in the NGT arm refused subsequent re-treatment. The remaining 5 patients were 
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given a second infusion at mean 4.9 (SD 2.1) days after the first procedure, using feces from the 
same donor that provided the initial inoculum. Per protocol, patients could choose the route of 
delivery for re-treatment; and all 5 requested NGT administration. 4 patients obtained cure 
after the second inoculation, resulting in an overall cure rate of 90% (80% in the NGT group and 
100% in the initial colonoscopy group, p=0.53). No patient relapsed within the predetermined 
8-week follow up after initial cure. Daily number of bowel movements changed from a median 
(IQR) of 6 (5-10) and 7 (6-10) in the colonoscopy and NGT groups, respectively, the day prior to 
FMT (p=0.436) to 1 (1-1) and 2 (1-2) 8 weeks after the infusion (p=0.165, see Fig.2).  
Secondary outcomes: Self-reported health rating using a standardized questionnaire scale of 1-
10, with 1 being the lowest, and 10 being “your best recent health baseline” increased over the 
study period from a median (IQR) of 5 (3-6) and 4 (2-5) in the colonoscopy and NGT groups, 
respectively, the day prior to FMT (p=0.436) to 8 (7-10) and 7 (5-8) 8 weeks after the infusion. 
The colonoscopy group had consistently higher health scores, accounted for by a higher 
reported score at day -1. When analyzing the absolute increment in scores, the groups did not 
differ (p=0.51).  
Adverse events deemed likely related included mild abdominal discomfort and bloating in 4 
patients (20%). One child treated colonoscopically had a transient fever of 38.8°C on day 2 that 
resolved spontaneously. There were several serious adverse events which were assessed as 
unrelated by the investigators and IRB, and reflect the relatively poor health of many with 
recurrent CDI. One patient died 12 weeks after the procedure, while hospitalized secondary to 
an acute exacerbation of chronic obstructive pulmonary disease, including bleb rupture 
requiring intubation and chest tube. Although she was treated for several weeks with 
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parenteral broad-spectrum antimicrobials, her CDI did not recur. Another patient died of 
metastatic laryngeal cancer 21 weeks after the procedure. A third patient was diagnosed with 
adenocarcinoma of the esophagus. A fourth patient, treated by the upper gastrointestinal 
route, was hospitalized for Fournier’s gangrene.  
Fecal Microbiota:  14 stool samples from 4 donors and 65 samples from 19 recipients (21 pre-
FMT and 44 at different time points post FMT) were analyzed. The Shannon Diversity Index of 
fecal microbiota obtained from recipients evaluated prior to FMT was consistently low 
(mean±SD, 2.52±0.77) and increased after FMT (3.82±0.74) to a diversity level comparable to 
that of the donors’ (4.20±0.51, p<0.001 for the difference between pre and post FMT; p=0.53 
for the difference between post FMT and donor stool) as shown in Figure 4. This level persisted 
over time, and there was no significant difference between the diversity index in stool samples 
obtained in the first week after the procedure and those obtained up to six months later 
(p=0.11; Supplementary Appendix). The route of administration made no difference in the 
mean Shannon Diversity Index obtained after FMT (3.79±0.64 in the colonoscopy group 
compared to 3.84±0.84 in the NGT group, p=0.245; Fig 5). The microbiota composition and 
trajectories after FMT can be viewed in Figures S3 and S4 in the Supplementary Appendix.    
Discussion: 
In this small randomized controlled feasibility study, we demonstrated that infusion of 
unrelated frozen donor stools is efficacious in treating patients with relapsing/recurring CDI 
with an overall cure rate of 90% at 8 weeks. Furthermore, NGT seems to be a viable route of 
administration for the inoculum, a distinct advantage in the elderly and debilitated patients 
that are prone to this condition who may not tolerate a colonoscopy or the sedation associated 
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with the procedure. These data are especially encouraging in view of our study population, 
consisting of patients with at least 3 recurrences of CDI or two episodes of CDI resulting in 
hospitalization, in which the reported cure rate with standard antimicrobial treatment falls to 
<30% [7]. Moreover, 95% of patients had been treated with previous prolonged vancomycin 
tapers and 70% of participants had been treated with fidaxomicin in the past, even further 
lowering the likelihood of obtaining cure with standard antimicrobial treatment. One 89 year 
old patient with refractory disease had 16 documented episodes of CDI in the preceding 15 
months, including 4 regular admissions and 2 admissions to the intensive-care unit. She was 
cured with two inocula and has been asymptomatic off treatment for 12 months.  
Interestingly, of the two treatment failures noted in our study, one patient refused a second 
treatment dose after the initial inoculum had no curative effect. Unbeknown to us, we later 
learned that this patient self-administered homemade fecal enemas daily for a week, using 
unprocessed stool from his roommate. He subsequently reported feeling well and being 
completely asymptomatic, but as per our study definitions he was considered a treatment 
failure. This example also brings to light the potential hurdles associated with regulating a 
readily available “biologic therapeutic”, as can also be evidenced by numerous “how to” 
manuals published on the internet.   
Though most of our patients were elderly, reflecting the main population in whom CDI 
develops, the mean age of our participants was only 54, influenced by the fact that we included 
three children in our study. This inclusion is important in view of the recent increase in the 
number of pediatric cases of CDI, including a growing population of children with 
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recurrent/refractory disease [1,32,33]. All three pediatric patients were cured after 
administration of a single inoculum. 
Since completing administration of FMT to the 20 study subjects, we have performed an 
additional 11 “expanded access” clinical administrations of FMT using frozen inocula from 
unrelated donors with a success rate of 90.9%. All were delivered via NGT.   
While a previous study demonstrated the superiority of FMT over standard antimicrobial 
treatment [21], the authors examined instillation of fresh donor stools. This strategy has several 
potential disadvantages, including the need for maintaining a readily available pool of donors, 
maintaining updated medical screening of donors, and, finally, the challenging logistics of 
obtaining the stool sample, processing the inoculum and delivering the FMT within a limited 
timeframe. The use of frozen inocula addresses many of these obstacles by allowing 
identification and screening of donors ahead of time and establishment of a bank of pre-
processed and vetted material that is a readily-available on short notice. The banking of donor 
stools also allows the added safety of following donors for a period of time and retesting for 
infectious diseases that could potentially have been latent at the time of donation, prior to 
administration of the inoculum. The optimal “shelf life” of the inoculate is still unclear, but in 
our study the longest an inoculum was stored prior to clinical use was 156 days (mean 79.3 
days).   
Despite numerous reports of successful resolution of CDI by FMT, the treatment has yet to 
become an available therapeutic option for many patients. This lack of availability not only 
deprives patients of the potential benefits of the procedure, but encourages patients to seek 
unregulated sources of information and alternative FMT providers, leading to treatment with 
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unscreened fecal materials. As mentioned, this limitation can be partly explained by the 
logistical hurdles associated with the procedure [34]. Another inhibiting factor is the fact that 
the available data are mostly based on retrospective case series and include only a single 
randomized trial [21,24,25] to date, making practitioners cautious about adopting FMT as a 
viable treatment alternative. The variability in patient population, donor selection, inoculum 
preparation and route and volume of administration all make pooling of published results 
challenging. Our study protocol (attached in the Supplementary Appendix) may be of value in 
standardizing FMT, and we hope, if adopted by others, will make future outcome data 
comparable between institutions.  
A major limitation of our study is the small sample size. Nevertheless, our results were 
comparable to those in the literature when using fresh donor stools. Of particular importance is 
the fact that delivery of the inoculum through the upper gastrointestinal tract seems to be 
comparable to that of colonoscopic delivery, thus eliminating the need for sedation, anesthetic 
risks, and colonic “clean out.”  Possible vomiting and aspiration is a concern with upper GI 
delivery, although we did not observe this complication in our study subjects or in 11 
subsequent cases for care.  We have now addressed this concern in part by further 
concentrating and encapsulating this inoculum in Capsugel DR hypromellose capsules, which 
resist dissolution in acidic environments. We are now studying oral delivery of frozen 
encapsulated material as the next logical step in making FMT more accessible to patients.    
In conclusion, in our initial feasibility study, FMT using a frozen inoculum from unrelated donors 
was effective in treating relapsing CDI, even in patients with multiple recurrences. NGT 
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Table 1. Select baseline characteristics of study population stratified by treatment group. 
 Initial Colonoscopy Nasogastric Tube  p-value 
aAge (years) 50.4±28.8 58.6±19.6 0.739 
bFemale gender 6 (60) 5 (50) 1.00 
bTime since initial CDI (months) 7 (3-34) 12 (3-66) 1.00 
bHospital-acquired CDI 2 (20) 3 (30) 1.00 
cNumber of CDI recurrences prior to FMT 4 (2-7) 5 (3-16) 0.42 
bPrevious vancomycin taper 9 (90) 10 (100) 1.00 
bPrevious use of fidaxomycin 5 (50) 7 (70) 0.64 
bHospital admissions in the past due to CDI  6 (60) 7 (70) 1.00 
bInpatient at time of FMT  2 (20) 3 (30) 1.00 
cNumber of BM 1 day prior to FMT 6 (4-13) 7 (5-13) 0.43 
cHealth status 1 day prior to FMT 5 (2-7) 4 (1-10) 0.21 
 






































Figure 2: Number of bowel movements per 24 hours in study population. 
 
Legend: Shown are mean number of daily bowel movements (BM) in both study arms. Baseline 
represents reported BM prior to contracting C. difficile as reported by the patients. 6-month follow up is 
























Figure 3: Reported health status over time in study population  
 
Legend: Shown are mean scores of subjective well-being over time as reported using standardized 
questionnaire with a scale 1-10, 1 being the lowest. The colonoscopy group had consistently higher 
scores, accounted for by a mean higher reported score at day -1. When analyzing the absolute 























Figure 4: Microbiota Diversity in Patients Before and After FMT, as Compared with Diversity in the 
Donors.  
 
Legend: Shown is microbiota diversity in fecal samples obtained from fecal microbiota transplant 
recipients before and after the procedure, as compared with the donors, expressed by the Shannon 
Diversity Index. The box-and-whisker plots indicate interquartile ranges (boxes), medians (red horizontal 
























Figure 5: Microbiota Diversity in CDI Patients after FMT, Comparing Initial Route of Administration. 
 
Legend: Shown is microbiota diversity in fecal samples obtained from fecal microbiota transplant 
recipients before and after the procedure, stratified by treatment route and expressed by the Shannon 
Diversity Index. The box-and-whisker plots indicate interquartile ranges (boxes), medians (red horizontal 
lines), and range (whiskers). CDI=Clostridium difficile infection; FMT=fecal microbiota transplant; 
SDI=Shannon diversity index. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
